# Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Study · id `cardio:ct-nct01994889` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01994889](<https://clinicaltrials.gov/study/NCT01994889>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01994889

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 441 participants.

## Technical summary

Registry record NCT01994889. Randomized; quadruple masking; primary purpose treatment. Start 2013-12-09 (actual); primary completion 2018-02-07 (actual). Results posted on 2019-04-03.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 441 participants (enrolled count; ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Started: 2013-12-09 (actual) (ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Primary completion: 2018-02-07 (actual) (ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Completion: 2018-02-07 (actual) (ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Results first posted: 2019-04-03 (ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Countries: United States; Belgium; Brazil; Canada; Czechia; France; Germany; Italy; Japan; Netherlands; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT01994889, source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01994889-2019-04-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy
- Acronym: ATTR-ACT
- Condition: Transthyretin (TTR) Amyloid Cardiomyopathy
- Intervention (Drug): Tafamidis
- Intervention (Drug): Tafamidis
- Intervention (Drug): Placebo
- Lead sponsor: Pfizer
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry intervention name matches this record: Tafamidis (`cardio:tafamidis`)
- Registry lists this organization as the lead sponsor: Pfizer (`cardio:org-pfizer`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy (`cardio:pubmed-30145929`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial) (`cardio:pubmed-33220323`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial \[ATTR-ACT\]) (`cardio:pubmed-33667442`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial (`cardio:pubmed-36723935`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial (`cardio:pubmed-37966817`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 383789cd1d6556983c73bbf35b3e4c214f05ace447f73ff31f7021f8b6778d30
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
